- Home
- ACLX vs IRTC Comparison
ACLX vs IRTC Comparison
Compare ACLX & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLX
- IRTC
- Stock Information
- Founded
- ACLX 2015
- IRTC 2006
- Country
- ACLX United States
- IRTC United States
- Employees
- ACLX N/A
- IRTC N/A
- Industry
- ACLX Biotechnology: Pharmaceutical Preparations
- IRTC Medical/Dental Instruments
- Sector
- ACLX Health Care
- IRTC Health Care
- Exchange
- ACLX Nasdaq
- IRTC Nasdaq
- Market Cap
- ACLX 3.3B
- IRTC 3.1B
- IPO Year
- ACLX 2022
- IRTC 2016
- Fundamental
- Price
- ACLX $62.02
- IRTC $100.96
- Analyst Decision
- ACLX Strong Buy
- IRTC Strong Buy
- Analyst Count
- ACLX 13
- IRTC 10
- Target Price
- ACLX $110.82
- IRTC $120.20
- AVG Volume (30 Days)
- ACLX 799.4K
- IRTC 365.8K
- Earning Date
- ACLX 05-08-2025
- IRTC 05-01-2025
- Dividend Yield
- ACLX N/A
- IRTC N/A
- EPS Growth
- ACLX N/A
- IRTC N/A
- EPS
- ACLX N/A
- IRTC N/A
- Revenue
- ACLX $107,936,000.00
- IRTC $591,839,000.00
- Revenue This Year
- ACLX N/A
- IRTC $17.46
- Revenue Next Year
- ACLX $96.17
- IRTC $16.93
- P/E Ratio
- ACLX N/A
- IRTC N/A
- Revenue Growth
- ACLX N/A
- IRTC 20.13
- 52 Week Low
- ACLX $47.88
- IRTC $55.92
- 52 Week High
- ACLX $107.37
- IRTC $128.52
- Technical
- Relative Strength Index (RSI)
- ACLX 47.82
- IRTC 46.56
- Support Level
- ACLX $59.38
- IRTC $98.41
- Resistance Level
- ACLX $61.52
- IRTC $104.12
- Average True Range (ATR)
- ACLX 4.80
- IRTC 6.10
- MACD
- ACLX 0.09
- IRTC -0.15
- Stochastic Oscillator
- ACLX 70.31
- IRTC 50.18
About ACLX Arcellx Inc.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
About IRTC iRhythm Technologies Inc.
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.